Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-κB and AP-1 and also reduced osteoclast activity and survival

Biochemical and Biophysical Research Communications

Volumn 337, Issue 3, 2005, Pages 815-823

  Hwang, Yun Ha ^a,b   Jung, Wook Lee ^b   Hahm, Eun Ryeong ^a   Kyung, Chae Jung ^a   Ju, Hyung Lee ^a   Chi, Hoon Park ^a   Ho, Sung Rhee ^a   Je, Man Ryu ^b   Kim, Hyun Kyung ^a   Yang, Chul Hak ^a  

^a Seoul National University   (South Korea)

^b DongWha Pharm Ind Co   (South Korea)

Author keywords

AP 1; Bone resorption; Momordin I; NF B; Osteoclast; Osteoclastogenesis; RANKL; Survival

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MOMORDIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN C FOS; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL CULTURE; CELL FUNCTION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DENTIN; HUMAN; HUMAN CELL; LIFESPAN; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELLS; MICE; MICE, INBRED STRAINS; NF-KAPPA B; OLEANOLIC ACID; OSTEOCLASTS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

AMPELOPSIS RADIX; ANIMALIA;

EID: 26844528924     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.09.113     Document Type: Article

References (32)

1. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
2. E. Jimi, I. Nakamura, H. Amano, Y. Taguchi, T. Tshrukai, M. Tamura, N. Takahashi, and T. Suda Osteoclast function in activated by osteoblastic cells through a mechanism involving cell-to-cell contract Endocrinology 137 1996 2187 2190
3. E. Jimi, S. Akiyama, T. Tsurukai, N. Okahashi, K. Kobayashi, N. Udagawa, T. Nishihara, N. Takakashi, and T. Suda Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function J. Immunol. 163 1999 434 442
4. S. Khosla Minireview: the OPG/RANKL/RANK system Endocrinology 142 2001 5050 5055
5. Z.H. Lee, and H.H. Kim Signal transduction by receptor activator of nuclear factor κB in osteoclasts Biochem. Biophys. Res. Commun. 305 2003 211 214
6. H. Hotokezaka, E. Sakai, K. Kannaoka, K. Saito, K. Katsuo, H. Kitaura, N. Yoshida, and K. Nakayama U0126 and PD98059, specific inhibitors of MEK, accelerated differentiation on RAW264.7 cells into osteoclast-like cells J. Biol. Chem. 277 2002 47366 47372
7. J.P. David, K. Sabapathy, O. Hoffmann, M.H. Idarraga, and E.F. Wagner JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms J. Cell Sci. 115 2002 4317 4325
8. S.L. Teitelbaum, and F.P. Ross Genetic regulation of osteoclast development and function Nat. Rev. Genet. 4 2003 638 649
9. A.E. Grigoriadis, Z.Q. Wang, M.G. Cecchini, W. Hofstetter, R. Felix, H.A. Fleisch, and E.F. Wagner c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling Science 266 1944 443 448
10. G. Franzoso, L. Carlson, L. Xing, L. Poljak, E.W. Shores, K.D. Leonardi, T. Tran, B.F. Boyce, and U. Siebenlist Requirment for NF-κB in osteoclast and B-cell development Genes Dev. 11 1997 3482 3496
11. V. Iotsova, J. Caamano, J. Loy, Y. Yang, A. Lewin, and R. Bravo Osteopetrosis in mice lacking NF-κB1 and NF-κB2 Nat. Med. 3 1997 1285 1289
12. M.A. Lomaga, W.C. Yeh, I. Sarosi, G.S. Duncan, C. Furlonger, A. Ho, S. Morony, C. Capparelli, G. Van, S. Kaufman, A. van der Heiden, A. Itie, A. Wakeham, W. Khoo, T. Sasaki, Z. Cao, J.M. Penninger, C.J. Paige, D.L. Lacey, C.R. Dunstan, W.J. Boyle, D.V. Goeddel, and T.W. Mak TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling Genes Dev. 13 1999 1015 1024
13. B. Noble Bone microdamage and cell apoptosis European Cells Materials 6 2003 45 56
14. L. Xing, and B.F. Boyce Regulation of apoptosis in osteoclasts and osteoblastic cells Biochem. Biophys. Res. Commun. 26 2005
15. A. Gingery, E. Bradley, A. Shaw, and M.J. Oursler Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NF-κB pathways to maintain osteoclast survival J. Cell. Biochem. 89 2003 165 179
16. G.A. Rodan, and T.J. Martin Therapeutic approaches to bone diseases Science 289 2000 1508 1514
17. H. Takatsuna, M. Asagiri, T. Kubota, K. Oka, T. Osada, C. Sugiyama, H. Saito, K. Aoki, K. Ohya, H. Takayanagi, and K. Umezawa Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through downregulation of NFATc1 J. Bone Miner. Res. 20 2005 653 662
18. A.C. Bharti, Y. Takada, and B.B. Affarwal Curcumin (Diferuloylmethane) inhibits receptor activator of NF-κB ligand-induced NF-κB activation in osteoclast precursors and suppresses osteoclastogenesis J. Immunol. 172 2004 5940 5947
19. K. Ozaki, Y. Kawata, S. Amano, and S. Hanazawa Stimulatory effect of curcumin on osteoclast apoptosis Biochem. Pharmacol. 59 2000 1577 1581
20. D.K. Lee, B.S. Kim, S.G. Lee, H.J. Gwon, E.Y. Moon, H.S. Hwang, S.K. Seong, M.S. Lee, M.J. Lim, H.J. Sung, D.H. Shin, S.J. Yoon, and C.H. Yang Momordins inhibit both AP-1 function and cell proliferation Anticancer Res. 18 1998 119 124
21. S. Park, D.K. Lee, Y.H. Hwang, and C.H. Yang Momordin I, a compound of Ampelopsis radix, inhibits AP-1 activation induced by phorbol ester Cancer Lett. 152 2000 1 8
22. J.H. Kim, E.M. Ju, D.K. Lee, and H.J. Hwang Induction of apoptosis by momordin I in promyelocytic leukemia (HL-60) cells Anticancer Res. 22 2002 1885 1889
23. S.C. Manolagas Birth and death of bone cells: basic regulatory mechanism and implications for the pathogenesis and treatment of osteoporosis Endocr. Rev. 21 2000 115 137
24. N. Takahashi, H. Yamana, S. Yoshiki, G.D. Roodman, G.R. Mundy, S.J. Jones, A. Boyde, and T. Suda Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures Endocrinology 122 1988 1373 1382
25. S.C. Manolagas, S. Kousteni, and R.L. Jilka Sex steroids and bone Recent Prog. Horm. Res. 57 2002 385 409
26. K. Matsuo, and N. Ray Osteoclasts, mononuclear, phagocytes and c-Fos: new insight into osteoimmunology Keio. J. Med. 53 2004 78 84
27. K. Matsuo, J.M. Owens, M. Tonko, C. Elliott, T.J. Chambers, and E.F. Wagner Fosl1 is a transcriptional target of c-Fos during osteoclast differentiaton Nat. Genet. 24 2000 184 187
28. A. Fleischmann, F. Hafezi, C. Elliott, C.E. Reme, U. Ruther, and E.F. Wagner Fra-1 replaces c-Fos-dependent functions in mice Genes Dev. 14 2000 2695 2700
29. K. Matsuo, D.L. Galson, C. Zhao, L. Peng, C. Laplace, K.Z. Wang, M.A. Bachler, H. Amano, H. Aburatani, H. Ishikawa, and E.F. Wagner Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos J. Biol. Chem. 279 2004 26475 26480
30. H. Takayanagi, S. Kim, T. Koga, H. Nishina, M. Isshiki, H. Yoshida, A. Saiura, M. Isobe, T. Yokochi, J. Inoue, E.F. Wagner, I.W. Mak, T. Kodama, and T. Taniguchi Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts Dev. Cell 3 2002 889 901
31. N. Ishida, K. Hayashi, M. Hoshijima, T. Ogawa, S. Koga, Y. Miyatake, M. Kumegawa, T. Kimura, and T. Takeya Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator J. Biol. Chem. 277 2002 41147 41156
32. H. Takayanagi, S. Kim, K. Matsuo, H. Suzuki, T. Suzuki, K. Sato, T. Yokochi, H. Oda, K. Nakamura, N. Ida, and E.F. Wagner RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β Nature 416 2002 744 749